IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.306
AS - Asia 1.732
EU - Europa 968
SA - Sud America 608
Continente sconosciuto - Info sul continente non disponibili 282
AF - Africa 48
OC - Oceania 2
Totale 7.946
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.218
SG - Singapore 749
BR - Brasile 521
HK - Hong Kong 398
IE - Irlanda 312
IT - Italia 224
VN - Vietnam 140
BD - Bangladesh 122
CN - Cina 117
DE - Germania 98
TR - Turchia 61
FR - Francia 53
SE - Svezia 52
IN - India 43
GB - Regno Unito 42
CA - Canada 36
NL - Olanda 35
AR - Argentina 34
FI - Finlandia 30
MX - Messico 28
RU - Federazione Russa 26
IQ - Iraq 21
AT - Austria 16
ES - Italia 14
UA - Ucraina 13
CO - Colombia 12
ID - Indonesia 12
PK - Pakistan 12
EC - Ecuador 11
LT - Lituania 11
PL - Polonia 11
ZA - Sudafrica 11
UZ - Uzbekistan 10
BE - Belgio 8
CL - Cile 8
SA - Arabia Saudita 8
TN - Tunisia 8
JP - Giappone 7
PY - Paraguay 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
EG - Egitto 6
KE - Kenya 6
MA - Marocco 6
AL - Albania 5
IL - Israele 5
VE - Venezuela 5
PH - Filippine 4
RS - Serbia 4
SN - Senegal 4
UY - Uruguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
GT - Guatemala 3
HN - Honduras 3
JM - Giamaica 3
JO - Giordania 3
PE - Perù 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BH - Bahrain 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
KG - Kirghizistan 2
LB - Libano 2
MY - Malesia 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
CH - Svizzera 1
CI - Costa d'Avorio 1
ET - Etiopia 1
HU - Ungheria 1
IS - Islanda 1
KZ - Kazakistan 1
MK - Macedonia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
TH - Thailandia 1
UG - Uganda 1
VC - Saint Vincent e Grenadine 1
Totale 7.664
Salva come PNG Salva come JPEG
Città #
Dallas 1.352
San Jose 542
Singapore 402
Hong Kong 396
Ashburn 315
Dublin 312
The Dalles 171
Chicago 166
Santa Clara 162
Council Bluffs 148
Boardman 137
São Paulo 53
Ho Chi Minh City 49
Istanbul 46
Phoenix 45
New York 44
Munich 38
Beijing 33
Assago 32
Los Angeles 31
Helsinki 26
Amsterdam 24
Milan 24
Abbeville 23
Princeton 23
Rio de Janeiro 23
Hanoi 22
Frankfurt am Main 21
Rome 15
Boston 13
Brasília 13
Brooklyn 13
Palermo 12
San Francisco 12
Belo Horizonte 10
Düsseldorf 10
Haiphong 10
Montreal 10
Naples 10
Orem 10
Vienna 10
Buffalo 9
Chennai 9
Houston 9
Porto Alegre 9
Tashkent 9
Warsaw 9
Charlotte 8
Hillsboro 8
Toronto 8
Atlanta 7
Bemidji 7
Brussels 7
Buenos Aires 7
Campinas 7
Guarulhos 7
Manchester 7
Mexico City 7
Minneapolis 7
Orlando 7
Paris 7
Quito 7
Ankara 6
Bexley 6
Birmingham 6
Brno 6
Columbus 6
Curitiba 6
Denver 6
Florence 6
Lahore 6
Memphis 6
Miami 6
Ottawa 6
Riyadh 6
Salvador 6
San Antonio 6
Tokyo 6
Baghdad 5
Las Vegas 5
London 5
Lugo 5
Milwaukee 5
Nairobi 5
New Delhi 5
Nuremberg 5
Philadelphia 5
Queens 5
Ribeirão Preto 5
Seattle 5
Stockholm 5
Thái Bình 5
Turin 5
Asunción 4
Betim 4
Bogotá 4
Cagliari 4
Catania 4
Contagem 4
Da Nang 4
Totale 5.169
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 154
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 111
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 108
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 105
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 99
Investigating biochemical markers of Acupuncture's effectiveness in managing climacteric syndrome in breast cancer patients: the FLAIR study 89
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update 87
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 86
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 85
Biomarkers: which ones do we really need today? 84
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 82
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 79
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 79
The use of platelets as a clinical tool in oncology: opportunities and challenges 78
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 77
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 75
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 72
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 69
Androgen receptor signaling pathways as a target for breast cancer treatment 69
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 68
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer. 67
Urinary Biomarkers in Tumors: An Overview 67
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 67
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 65
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 65
FAP inhibitors: are we really using the best method to evaluate the residence time? 64
Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives 64
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 63
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 63
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 63
Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. 63
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 62
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 62
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 62
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 62
Androgen receptor in breast cancer: The "5W" questions 62
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 60
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 60
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 60
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 60
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 59
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 59
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 58
TMB in NSCLC: A Broken Dream? 58
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 58
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 58
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 58
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 57
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 57
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 57
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 56
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 56
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 56
Expanding Roles of De Novo Lipogenesis in Breast Cancer 55
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 55
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 55
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 55
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 54
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 54
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 53
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 53
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 53
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 53
Urine telomerase: An important marker in the diagnosis of bladder cancer 52
Are we ready to use TMB in breast cancer clinical practice? 52
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 52
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 52
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 52
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 52
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? 52
Usefulness of immunological detection of the human telomerase reverse transcriptase 50
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 49
Explaining the aggressiveness of breast cancer in sub-Saharan African patients 49
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy 49
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 48
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 47
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 47
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 47
Why the complications of COVID-19 patients differ in elderly and young cancer patients 47
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 47
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma 47
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 46
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 46
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report 46
Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN 46
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 46
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis 44
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 44
The current status of biomarkers for bladder cancer: progress and challenges 43
Can Macrophages Predict Response to Neoadjuvant Therapy in Lung Cancer? A Lesson from Breast Cancer. 43
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 42
Relevance of urine telomerase in the diagnosis of bladder cancer 42
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 42
New Biomarkers to Predict the Evolution of In Situ Breast Cancers 42
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 41
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 41
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer A case report 41
Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue 41
What to look for in cell-free DNA from breast cancer patients 40
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 40
Totale 6.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20264.245 313 965 545 415 150 167 515 326 312 288 108 141
2026/20271.018 104 128 522 264 0 0 0 0 0 0 0 0
Totale 7.946